PMID- 27650230
OWN - NLM
STAT- MEDLINE
DCOM- 20170515
LR  - 20181202
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
VI  - 352
IP  - 3
DP  - 2016 Sep
TI  - Increased Platelet-leukocyte Aggregates Are Associated With Myocardial No-reflow 
      in Patients With ST Elevation Myocardial Infarction.
PG  - 261-6
LID - S0002-9629(16)30333-0 [pii]
LID - 10.1016/j.amjms.2016.05.034 [doi]
AB  - OBJECTIVE: We aimed to investigate the association between platelet-leukocyte 
      aggregates (PLA) levels on admission and the risk of myocardial no-reflow in 
      patients with ST elevation myocardial infarction (STEMI) who underwent primary 
      percutaneous coronary intervention (PCI). METHODS: A total of 83 patients with 
      STEMI undergoing primary PCI were included in the current study. 
      Platelet-leukocyte conjugates (PLA), including platelet-monocyte aggregates 
      (PMA), platelet-neutrophil aggregates (PNA) and platelet-lymphocyte aggregates 
      were studied by flow cytometry in peripheral venous blood. No-reflow was defined 
      as coronary blood flow grade thrombolysis in myocardial infarction </=2 or 
      thrombolysis in myocardial infarction 3 and myocardial blush grade </=2. RESULTS: 
      No-reflow was observed in 19 patients (22.9%). Compared with the reflow group, 
      the level of PNA (76.5 +/- 13.3) and PMA (90.3 +/- 5.2) before PCI no-reflow group 
      was significantly higher than that in normal reflow (P < 0.001). Using multiple 
      logistic regression analysis, PNA (odds ratio [OR] = 1.179; 95% CI: 1.035-1.342; 
      P = 0.013) and PMA (OR = 1.248; 95% CI: 1.040-1.498; P = 0.017) were found to be 
      a significant predictor of no-reflow together with pain to balloon time (OR = 
      1.022; 95% CI: 1.002-1.041; P = 0.028), estimated glomerular filtration rate (OR 
      = 1.311; 95% CI: 1.009-1.856; P = 0.047) and higher thrombus burden (OR = 0.061; 
      95% CI: 0.006-0.658; P = 0.021). Receiver operating characteristic curve analysis 
      revealed that PNA (area under the curve = 0.881; 95% CI: 0.809-0.952; P < 0.001), 
      PMA (area under the curve = 0.794; 95% CI: 0.699-0.889; P < 0.001) have important 
      predictive value for the myocardial no-reflow. CONCLUSIONS: Our study indicated 
      that preprocedural increased PLA levels display a significantly independent 
      association with no-reflow phenomenon after PCI. Increased PLA levels may predict 
      the development of no-reflow phenomenon in patients with STEMI who underwent PCI.
CI  - Copyright (c) 2016 Southern Society for Clinical Investigation. Published by 
      Elsevier Inc. All rights reserved.
FAU - Ren, Faxin
AU  - Ren F
AD  - Department of Cardiology, Yuhuangding Hospital, Yantai, Shandong, P.R. China.
FAU - Mu, Nan
AU  - Mu N
AD  - Department of Gynecology, Yuhuangding Hospital, Yantai, Shandong, P.R. China.
FAU - Zhang, Xia
AU  - Zhang X
AD  - Department of Clinical Laboratories, The Affiliated Yantai Yuhuangding Hospital 
      of Qingdao University, Yantai, Shandong, P.R. China.
FAU - Tan, Jinxi
AU  - Tan J
AD  - Department of Cardiology, Yuhuangding Hospital, Yantai, Shandong, P.R. China.
FAU - Li, Liudong
AU  - Li L
AD  - Department of Cardiology, Yuhuangding Hospital, Yantai, Shandong, P.R. China.
FAU - Zhang, Chuanhuan
AU  - Zhang C
AD  - Department of Cardiology, Yuhuangding Hospital, Yantai, Shandong, P.R. China.
FAU - Dong, Mei
AU  - Dong M
AD  - Department of Cardiology, Yuhuangding Hospital, Yantai, Shandong, P.R. China. 
      Electronic address: dongmei0212@126.com.
LA  - eng
PT  - Journal Article
DEP - 20160609
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/administration & dosage/therapeutic use
MH  - Blood Platelets/metabolism/*pathology
MH  - Clopidogrel
MH  - Coronary Angiography
MH  - *Coronary Circulation
MH  - Coronary Thrombosis/blood/prevention & control
MH  - Electrocardiography
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Leukocytes/metabolism/*pathology
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*blood/epidemiology/immunology/surgery
MH  - No-Reflow Phenomenon/*blood/epidemiology/immunology
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/administration & dosage/therapeutic use
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Ticlopidine/administration & dosage/analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Acute myocardial infarction
OT  - Inflammation reaction
OT  - No-reflow
OT  - Platelet-leukocyte aggregates
OT  - Thrombosis
EDAT- 2016/09/22 06:00
MHDA- 2017/05/16 06:00
CRDT- 2016/09/22 06:00
PHST- 2016/03/02 00:00 [received]
PHST- 2016/05/08 00:00 [revised]
PHST- 2016/05/17 00:00 [accepted]
PHST- 2016/09/22 06:00 [entrez]
PHST- 2016/09/22 06:00 [pubmed]
PHST- 2017/05/16 06:00 [medline]
AID - S0002-9629(16)30333-0 [pii]
AID - 10.1016/j.amjms.2016.05.034 [doi]
PST - ppublish
SO  - Am J Med Sci. 2016 Sep;352(3):261-6. doi: 10.1016/j.amjms.2016.05.034. Epub 2016 
      Jun 9.